Recently, LW402, a new-generation oral JAK1-selective inhibitor independently developed by LWBP, has completed the enrollment of all subjects in a Clinical II study of atopic dermatitis (AD).
Blinded data showed that LW402 tablets had a far superior level of EASI50/75/90/100 response: among subjects who have completed 4-week/12-week administration(including multiple dosing groups and 1 placebo group), more than 50% (4-week) and 80% (12-week) reached the therapeutic endpoint (EASI50), respectively; nearly 20% of patients reached curative EASI100 at week 12, providing a substantial generational advantage.